Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children

Clinical Pharmacokinetics
Hannu KokkiIlkka Ojanperä

Abstract

To evaluate the pharmacokinetics of four administration routes of oxycodone parenteral liquid (10 mg/mL), single intravenous and intramuscular injections and buccal and gastric administration, in children. Forty generally healthy children, aged 6-93 months, undergoing inpatient surgery. After induction of anaesthesia, children received a single dose of oxycodone 0.1 mg/kg intravenously (n = 9), intramuscularly (n = 10), buccally (n = 11) or via an orogastric tube into the stomach (n = 10). Regular blood samples were collected up to 12 hours, and plasma was analysed for oxycodone using gas chromatography-mass spectrometry (limit of quantification 1 microg/L). The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration. The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group. The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes i...Continue Reading

References

Oct 1, 1991·Acta Anaesthesiologica Scandinavica·E KalsoT Tammisto
Sep 1, 1988·Clinical Pharmacology and Therapeutics·D S WeinbergK M Foley
Jul 1, 1994·British Journal of Clinical Pharmacology·K T OlkkolaE L Maunuksela
Feb 1, 1993·Journal of Pain and Symptom Management·R PöyhiäE Kalso
Feb 1, 1997·Acta Anaesthesiologica Scandinavica·A TakalaK T Olkkola
Oct 15, 1998·British Journal of Anaesthesia·J M Alexander-Williams, D J Rowbotham
Apr 13, 2000·Journal of Clinical Pharmacology·H KokkiM Heikkinen
Jan 17, 2002·European Journal of Clinical Pharmacology·H KokkiM Karvinen
Mar 22, 2003·Clinical Pharmacokinetics·Hannu KokkiPekka Suhonen
Oct 10, 1959·Lancet·G J BRITTAIN

❮ Previous
Next ❯

Citations

Dec 22, 2007·Journal of Palliative Medicine·James F Cleary
Jun 29, 2006·Clinical Pharmacokinetics·Hannu KokkiIlkka Ojanperä
Mar 8, 2013·Trends in Pharmacological Sciences·Klaus T OlkkolaEija A Kalso
Mar 13, 2014·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Katherine L Boyle, Christopher D Rosenbaum
Apr 24, 2012·Expert Opinion on Pharmacotherapy·Hannu KokkiSari Sjövall
Apr 28, 2010·Expert Review of Neurotherapeutics·Mellar P Davis
Mar 1, 2012·Drug Development and Industrial Pharmacy·Vinay PanditSarasija Suresh
Oct 6, 2007·Expert Opinion on Drug Metabolism & Toxicology·Catherine Tom-Revzon
Sep 23, 2014·Current Medical Research and Opinion·Charles E Argoff, Ernest A Kopecky
Jul 6, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Matthew G KestenbaumJ Cameron Muir
Dec 25, 2007·The Journal of Pediatrics·Martin HewittRichard Hain
Oct 16, 2007·Pediatric Clinics of North America·Stefan J Friedrichsdorf, Tammy I Kang
Aug 5, 2009·Journal of Clinical Pharmacy and Therapeutics·L Lindell-OsuagwuH Kokki
May 28, 2008·Paediatric Anaesthesia·Richard HowardUNKNOWN Association of Paediatric Anaesthetists of Great Britain and Ireland
Mar 24, 2006·Journal of Clinical Pharmacology·Ahmed El-TahtawyBruce E Reidenberg
Jan 5, 2014·Acta Anaesthesiologica Scandinavica·P VälitaloH Kokki
Sep 24, 2015·Pain Practice : the Official Journal of World Institute of Pain·Joseph V PergolizziRobert Taylor
Jul 26, 2005·Peptides·Richard J Bodnar, Gad E Klein
Nov 12, 2016·Expert Review of Neurotherapeutics·Susanna Porela-TiihonenHannu Kokki
Oct 26, 2016·British Journal of Clinical Pharmacology·Merja KokkiHannu Kokki
Oct 19, 2017·Current Medical Research and Opinion·A PiirainenH Kokki
Apr 1, 2009·The Clinical Journal of Pain·Anna AxelinLiisa Lehtonen
Jun 18, 2005·Paediatric Anaesthesia·Marja-Leena PokelaKlaus T Olkkola
Apr 14, 2009·Therapeutic Drug Monitoring·Simona PichiniRafael de laTorre
Jan 18, 2019·Clinical Pharmacokinetics·Mari KinnunenMerja Kokki
Apr 23, 2019·European Journal of Drug Metabolism and Pharmacokinetics·James C ThigpenSam Harirforoosh
Feb 25, 2009·Clinical Pharmacology and Therapeutics·A LiukasK T Olkkola
Mar 18, 2021·Pharmacogenomics·Nelly N UmukoroSenthilkumar Sadhasivam
Aug 26, 2021·World Journal of Otorhinolaryngology - Head and Neck Surgery·Daniel R Jensen
Sep 2, 2021·Paediatric Anaesthesia·James D MorseBrian J Anderson
Sep 17, 2008·Joint Commission Journal on Quality and Patient Safety·Debra B GordonDianne M Danis
Sep 21, 2016·Pediatrics·Joseph D TobiasUNKNOWN COMMITTEE ON DRUGS

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.